TTY Biopharm Company Limited

TPEX:4105 Stock Report

Market Cap: NT$18.4b

TTY Biopharm Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for TTY Biopharm.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth59.6%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly

Apr 02
Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly

Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?

Mar 15
Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?

Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?

Feb 25
Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?

TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Feb 07
TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts Substantially

Jan 19
TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts Substantially

What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Jan 10
What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet

Dec 15
TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet

How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?

Nov 25
How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as TTY Biopharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TPEX:4105 - Analysts future estimates and past financials data (TWD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/20245,8261,1201,0171,122N/A
6/30/20245,7261,1249821,087N/A
3/31/20245,6131,1711,0991,211N/A
12/31/20235,5061,1299861,085N/A
9/30/20235,3941,168758891N/A
6/30/20235,2871,1301,0911,219N/A
3/31/20235,1911,1061,0211,142N/A
12/31/20225,0621,0941,1001,236N/A
9/30/20224,9971,1931,2941,399N/A
6/30/20224,7311,1091,0151,116N/A
3/31/20224,6098561,1561,247N/A
12/31/20214,5368321,1821,256N/A
9/30/20214,270751873937N/A
6/30/20214,235720768937N/A
3/31/20214,092874444619N/A
12/31/20204,222924344526N/A
9/30/20204,130693455646N/A
6/30/20204,255787894980N/A
3/31/20204,4458601,1231,191N/A
12/31/20194,4669001,1391,210N/A
9/30/20194,4471,2361,2411,298N/A
6/30/20194,2041,263932980N/A
3/31/20194,1101,499819893N/A
12/31/20184,0361,4619871,074N/A
9/30/20184,1021,6968991,013N/A
6/30/20184,2401,631N/A1,099N/A
3/31/20184,1731,379N/A1,237N/A
12/31/20174,0791,345N/A997N/A
9/30/20173,8741,088N/A980N/A
6/30/20173,7651,023N/A1,031N/A
3/31/20173,7951,134N/A1,109N/A
12/31/20163,7611,193N/A1,227N/A
9/30/20163,7331,536N/A1,083N/A
6/30/20163,6121,565N/A938N/A
3/31/20163,3891,393N/A947N/A
12/31/20153,1951,211N/A639N/A
9/30/20153,0581,133N/A698N/A
6/30/20152,929986N/A725N/A
3/31/20152,969829N/A593N/A
12/31/20142,980780N/A578N/A
9/30/20142,976196N/A409N/A
6/30/20142,99594N/A619N/A
3/31/20142,957124N/A1,200N/A
12/31/20133,110587N/A535N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 4105's forecast earnings growth is above the savings rate (1.1%).

Earnings vs Market: Insufficient data to determine if 4105's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 4105's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 4105's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 4105's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 4105's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y